Following Priority Review, Dupixent is now available to patients as young as 12 yearswith inadequately controlled CRSwNP ...

EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicals ...

Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and a subset of adenocarcinomas, offering potential indications to assess clinical activity ...

ROCKVILLE, MD, USA I 15, 2024 I MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and ...

Brenetafusp is clinically active as monotherapy and in combination with chemotherapy in heavily pre-treated, platinum-resistant ovarian cancer patients T cell fitness gene expression signature in ...

Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus ...

Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease ...

SUZHOU, China I 13, 2024 I MediLink Therapeutics (MediLink) today presented clinical data for YL201, a novel B7H3-targeting antibody drug conjugate ...

TOKYO, Japan & BASKING RIDGE, NJ, USA I 13, 2024 I Results from the DESTINY-Breast12 phase 3b/4 trial showed that ENHERTU® (trastuzumab ...

NEW YORK, NY, USA I 13, 2024 I OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody ...

NEW YORK, NY, USA I September 14, 2024 I Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against ...

WILMINGTON, DE, USA I 14, 2024 I Incyte (Nasdaq:INCY) today announced new early clinical data for INCB123667, a highly selective, potential ...